Freeline Therapeutics Holdings plc announced that on March 31, 2022, the Company granted its newly hired Chief Scientific Officer, Henning Stennicke, PhD, and two other newly hired employees non-statutory options to purchase an aggregate of 240,000 and 159,000 of the Company’s ordinary shares, respectively.
April 4, 2022
· 2 min read